Efficacy and Safety Trials Results of Complement Inhibitors

EP: 1.PNH Overview and Pathophysiology

EP: 2.Intravascular and Extravascular Hemolysis MoA in PNH

EP: 3.Utilizing Health Information Technology to Bridge Gaps in PNH Treatment Programming

EP: 4.Key Treatment Considerations for Patients Diagnosed With PNH

EP: 5.Complement System Role in PNH Treatment Approach

EP: 6.Eculizumab Impact on PNH Treatment Landscape and Unmet Needs in PNH Management

EP: 7.Efficacy End Points For PNH Treatment

Now Viewing

EP: 8.Efficacy and Safety Trials Results of Complement Inhibitors

EP: 9.Treatment Adherence and Cost Considerations Surrounding Various Routes of PNH Treatment Administration

EP: 10.Investigational Therapies Paving New PNH Treatment Pathways

EP: 11.Key Financial Factors Associated With Typical PNH Treatment Journey

EP: 12.Navigating Transfusion Requirements in PNH Treatment

EP: 13.Considerations for Managing PNH Treatment Complications

EP: 14.Infection Risk Management Counseling For Patients Receiving Treatment for PNH

EP: 15.Ensuring PNH Treatment Access and Adherence to Therapies

EP: 16.Financial Considerations Influencing Treatment Strategies in PNH Treatment Pathway

Video content above is prompted by the following:

Several complement inhibitors have been approved since eculizumab, including ravulizumab, a long-acting C5 inhibitor; danicopan, a factor D inhibitor; pegcetacoplan, a complement C3 inhibitor; and iptacopan, a complement factor B inhibitor. Please discuss the efficacy and safety results from the pivotal trials for each of these treatments.